Belite Bio Financial Statements
NASDAQ: BLTEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
154.93+2.41 (+1.58%)
Market open · Delayed 15 min · as of Oct 9, 3:29 PM ET
Belite Bio revenue and earnings
Belite Bio reported a net loss of $77.6 million, compared with a loss of $36.1 million a year earlier. Diluted earnings per share came in at -$2.31.
Summary generated from market data by MetaCap's automated system. Methodology
Belite Bio income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 84.21M | 40.00M | 31.67M | 12.82M | 9.80M | 5.74M |
| Research & Development | 45.38M | 29.94M | 24.84M | 8.87M | 7.42M | 3.69M |
| Selling, General & Admin | 38.83M | 10.06M | 6.82M | — | — | — |
| Operating Income | -84.21M | -40.00M | -31.67M | -12.82M | -9.80M | -5.74M |
| Interest Expense | 2.00K | 20.00K | 25.00K | 16.00K | — | 21.00K |
| Other Income (Expense) | 6.60M | 3.86M | 45.00K | 173.00K | 131.00K | -9.00K |
| Pretax Income | -77.61M | -36.14M | -31.62M | -12.65M | -9.67M | -5.75M |
| Income Tax | 0 | 6.00K | 9.00K | — | — | 1.00K |
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M | -5.75M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 | -0.65 |
| EPS (Diluted) | -2.31 | -1.18 | -1.19 | -0.63 | -1.01 | -0.65 |
| Shares Outstanding (Basic) | 33.54M | 30.54M | 26.59M | 19.98M | 9.57M | 8.79M |
| Shares Outstanding (Diluted) | 33.54M | 30.54M | 26.59M | 19.98M | 9.57M | 8.79M |
| EBITDA | -84.04M | -39.83M | -31.53M | -12.76M | -9.77M | -5.73M |
This table shows 6 annual periods of Belite Bio's income statement, from FY 2025 back to FY 2020, across 14 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow BLTE's reporting calendar. What is a income statement?